Bio-Path rises on positive preclinical data for obesity treatment

Bio Path Holdings

19/12/2024 12:55

** Shares of drug developer Bio-Path Holdings  BPTH.O  more
than double to $1.51 premarket 
    ** Co reports positive results from a preclinical study
testing its experimental treatment, BP1001-A, to treat obesity
and related metabolic diseases in Type 2 diabetes patients
     ** Co is testing BP1001-A to target a protein called Grb2
to increase insulin sensitivity and lower blood sugar levels in
patients
    ** Co says the trial confirmed the effectiveness of BP1001-A
in affecting insulin signaling
    ** Co says it has started animal studies to confirm the
efficacy of BP1001-A and plans to begin a early-stage trial in
testing the treatment in humans in 2025
    ** Up to last close, stock down 92.8% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))